A Fc-Engineering Approach to Define Functional Humoral Correlates of Immunity Against Ebola Virus

Gunn, Bronwyn M.; Lu, Richard; Slein, Matthew D.; Ilinykh, Philipp A.; Huang, Kai; Atyeo, Caroline; Schendel, Sharon L.; Kim, Jiyoung; Cain, Caitlin J.; Roy, Vicky; Suscovich, Todd J.; Takada, Ayato; Halfmann, Peter; Kawaoka, Yoshihiro; Pauthner, Matthias; Momo, Mambu; Goba, Augustine; Kanneh, Lansana; Andersen, Kristian G.; Schieffelin, John S.; Grant, Donald S.; Garry, Robert F.; Saphire, Erica Ollmann; Bukreyev, Alexander; Alter, Galit

doi:10.2139/ssrn.3608385

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody-dependent neutrophil phagocytosis (ADNP) and cellular phagocytosis (ADCP) assays were conducted as described previously 66, 67, 68 . Briefly, spike protein was carboxy coupled to blue, yellow-green, or red FluoSphere™ Carboxylate-modified microsphere, 0.2 μm (ThermoFisher) using NHS-ester linkages with Sulfo-NHS and EDC (Thermo Fisher).…”

Section: Methodsmentioning

confidence: 99%

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

Hassan

Shrihari

Gorman

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

SARS-CoV-2 variants that attenuate antibody neutralization could jeopardize vaccine efficacy and the end of the COVID-19 pandemic. We recently reported the protective activity of a single-dose intranasally-administered spike protein-based chimpanzee adenovirus-vectored vaccine (ChAd-SARS-CoV-2-S) in animals, which has advanced to human trials. Here, we assessed its durability, dose-response, and cross-protective activity in mice. A single intranasal dose of ChAd-SARS-CoV-2-S induced durably high neutralizing and Fc effector antibody responses in serum and S-specific IgG and IgA secreting long-lived plasma cells in the bone marrow. Protection against a historical SARS-CoV-2 strain was observed across a 100-fold vaccine dose range and over a 200-day period. At 6 weeks or 9 months after vaccination, serum antibodies neutralized SARS-CoV-2 strains with B.1.351 and B.1.1.28 spike proteins and conferred almost complete protection in the upper and lower respiratory tracts after challenge. Thus, in mice, intranasal immunization with ChAd-SARS-CoV-2-S provides durable protection against historical and emerging SARS-CoV-2 strains.

show abstract

Section: Methodsmentioning

confidence: 99%